Oncotelic identifies four-gene liver cancer signature

The presentation also outlined proposed AI-agent expansion and a planned research environment targeting 100 billion protein-related vectors.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Oncotelic Therapeutics, Inc. (OTLC) said Chief Business Officer Saran Saund presented at the 22nd Drug Discovery Strategic Summit on October 22, 2026. The presentation title referenced partitioning 29 million PubMed abstracts by disease. For liver cancer research, the company described combining literature analysis with gene-expression and survival analyses to identify a four-gene mTOR-related signature associated with patient outcomes and a candidate hepatocellular carcinoma population. The presentation also outlined a proposed expansion of the Partitioned Literature Aggregation framework through autonomous AI agents and a planned research environment targeting 100 billion protein-related vectors to support drug discovery across multiple disease areas.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

PubMed abstracts referenced in presentation title: 29 million PubMed abstracts Genes in mTOR-related signature: 4 genes Planned research environment target: 100 billion protein-related vectors

3 metrics

PubMed abstracts referenced in presentation title 29 million PubMed abstracts The presentation title describes partitioning them by disease.

Genes in mTOR-related signature 4 genes Signature associated with patient outcomes in liver cancer research.

Planned research environment target 100 billion protein-related vectors Outlined as part of the proposed PLA expansion.

Key Terms

Partitioned Literature Aggregation, gene-expression analyses, survival analyses, mTOR-related signature, +1 more

5 terms

Partitioned Literature Aggregation technical

"the Company’s Partitioned Literature Aggregation (“PLA”) framework"

gene-expression analyses technical

"combined with gene-expression and survival analyses"

survival analyses medical

"gene-expression and survival analyses"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did OTLC present about liver cancer?

OTLC described a liver-cancer research analysis combining literature review with gene-expression and survival analyses to identify a four-gene mTOR-related signature associated with patient outcomes and a candidate hepatocellular carcinoma population.

How does OTLC plan to expand its PLA framework?

The presentation outlined a proposed expansion through autonomous AI agents and a planned research environment targeting 100 billion protein-related vectors to support drug discovery across multiple disease areas.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/26/2026 - 09:00 AM EDT Accepted by SEC EDGAR 10/26/2026 - 09:00 AM EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

October 26, 2026

ONCOTELIC THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware

000-21990

13-3679168

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

29397 Agoura Road, Suite 107

Agoura Hills, CA 91301

(Address of principal executive offices and Zip Code)

Registrant’s telephone number, including area code

(650) 635-7000

Not applicable.

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of class		Trading Symbols		Name of each exchange on which registered
N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On October 22, 2026, Saran Saund, Chief Business Officer of Oncotelic Therapeutics Inc. made a presentation at the 22nd Drug Discovery Strategic Summit, October 21–22, 2026 at the Westin San Francisco Airport, Millbrae, California. The presentation titled “Partitioning 29 Million PubMed Abstracts by Disease Turns a Literature Review into a Discovery. A Four-Gene mTOR Signature Defining a Candidate Hepatocellular Carcinoma Population.”, is included as an exhibit to this Current Report on Form 8-K.

The presentation described the Company’s Partitioned Literature Aggregation (“PLA”) framework and its application in liver cancer research, where literature analysis was combined with gene-expression and survival analyses to identify a four-gene mTOR-related signature associated with patient outcomes. It also outlined the Company’s proposed expansion of PLA through autonomous AI agents and a planned research environment targeting 100 billion protein-related vectors to support drug discovery across multiple disease areas.

A hyperlink to the event is provided herewith: DDSS conference details

Disclaimer.

The information in Section 8.01 of this Current Report on Form 8-K, including the information set forth in exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Presentation 1
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.